IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Atazanavir and Lamivudine for Treatment Simplification (AtLaS)
This study has been completed.
Sponsor:
Catholic University of the Sacred Heart
Information provided by (Responsible Party):
Andrea De Luca, Catholic University of the Sacred Heart
ClinicalTrials.gov Identifier:
NCT00885482
First received: April 20, 2009
Last updated: February 23, 2015
Last verified: February 2015
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Objectives of the study:
- To verify the safety of the study treatment, defined as the persistent control of the virus' replication at 48 weeks after the simplification to lamivudine + atazanavir with ritonavir.
- To collect relevant information about the safety and the metabolic impact of this strategy in order to eventually design a non-inferiority randomized controlled trial for the evaluation of the safety and the efficacy of this strategy in the future.
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections | Drug: Lamiduvine (Epivir) Drug: Atazanavir (Reyataz) Drug: Ritonavir (Norvir) | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Atazanavir/Ritonavir + Lamivudine in Patients Stably Treated With Two NRTIs + Atazanavir/Ritonavir With Optimal Virologic Response. |
Resource links provided by NLM:
Further study details as provided by Andrea De Luca, Catholic University of the Sacred Heart:
Primary Outcome Measures:
- Number of Patients With Virological Failure (Two Consecutive Measures of HIV-RNA Higher Than 50 Copies/mL or a Single Measure Higher Than 1000 Copies/mL) Within 48 Weeks at intention-to.Treat Analysis [ Time Frame: 48 weeks ]
Secondary Outcome Measures:
- Time to Virological Failure at Survival Analysis [ Time Frame: 48 weeks ]
- Number of Patients With Viral Load Lower Than 50 Copies/mL at 48 Weeks at the Intention to Treat Analysis [ Time Frame: 48 weeks ]
- Evolution of CD4 Cell Count During the 48 Weeks [ Time Frame: 48 weeks ]
- Evolution of Adherence and Quality of Life During the 48 Weeks [ Time Frame: 48 weeks ]
- Evolution of Atazanavir Plasma Concentrations During the 48 Weeks [ Time Frame: 48 weeks ]
- Change of Metabolic Parameters at 48 Weeks [ Time Frame: 48 weeks ]
- Change of the Results of Neurocognitive Tests at 48 Weeks [ Time Frame: 48 weeks ]
- Change of Bone Density and of Subcutaneous Fat at 48 Weeks [ Time Frame: 48 weeks ]
| Enrollment: | 40 |
| Study Start Date: | May 2009 |
| Study Completion Date: | May 2011 |
| Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Single arm
Treatment simplification from a "standard" combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy.
|
Drug: Lamiduvine (Epivir)
Epivir 300 mg
Drug: Atazanavir (Reyataz)
Reyataz 300 mg
Drug: Ritonavir (Norvir)
Norvir 100 mg
|
Detailed Description:
Combined antiretroviral therapy has greatly improved the natural history of HIV infection/AIDS. Yet, it is associated with important short- and long- term side effects. In particular, nucleoside and nucleotide analogs may cause anemia, pancreatitis, mitochondrial dysfunction, lactic acidosis, lipoatrophy and reduction of renal function or of bone density.
Our study aims to verify the safety and efficacy of a simplification of a dual therapy (Lamivudine plus Atazanavir with Ritonavir), confiding on the potency and high genetic barrier of ritonavir-boosted agents.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients treated with the same regimen including 2NRTIs + ATV/r from at least 6 months
- Aged 18 years or older
- Who gave informed consent to the participation to the study
- With at least two viral load < 50 copies/mL in two consecutive determinations at least 3 months apart
- With CD4 cell count > 200 cells/μL and absence of any opportunistic infection or AIDS-related disease by one year at least
Exclusion Criteria:
- Pregnancy or breast feeding, desire of pregnancy in the short term
- Previous virological failure to antiretroviral therapy and/or previous exposure to mono- or dual therapies with reverse transcriptase nucleosidic analogues
- Patients with insufficient atazanavir plasma through concentration (lower than 0.23 μg/mL at 12th hour or 0.15 μg/mL at 24th hour) at screening and/or at baseline
- Patients with grade 3 or 4 laboratory abnormalities at screening (except for glucose or lipid serum levels and direct or indirect bilirubin)
- Concomitant treatment with antacids or proton-pump blockers or any other drug with known interactions or contraindications with the study medications
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00885482
Please refer to this study by its ClinicalTrials.gov identifier: NCT00885482
Locations
| Italy | |
| Catholic University of Sacred Heart | |
| Rome, Italy, 00168 | |
Sponsors and Collaborators
Catholic University of the Sacred Heart
Investigators
| Principal Investigator: | Andrea De Luca, MD | Catholic University of Sacred Heart |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Andrea De Luca, Professor, Catholic University of the Sacred Heart |
| ClinicalTrials.gov Identifier: | NCT00885482 History of Changes |
| Other Study ID Numbers: |
2009−011273−32 |
| Study First Received: | April 20, 2009 |
| Results First Received: | February 4, 2015 |
| Last Updated: | February 23, 2015 |
Keywords provided by Andrea De Luca, Catholic University of the Sacred Heart:
|
HIV/AIDS HAART Simplification |
Atazanavir Lamivudine treatment experienced |
Additional relevant MeSH terms:
|
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Atazanavir Sulfate Lamivudine |
HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |
ClinicalTrials.gov processed this record on August 21, 2017